DUNN JEFFREY W sold $55K of SIBN

DUNN JEFFREY W sold 3,575 shares of SI-BONE, Inc. (SIBN) at $15.25 on 2026-06-05.

Original reporting
SEC EDGAR · DUNN JEFFREY W
Published Jun 8, 2026, 9:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
medium confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

The article provides a fresh, primary-source datapoint on insider behavior (director sale size, price, and post-transaction holdings).

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing without other catalysts.

03

What to watch

Check whether other insiders are selling/buying around the same window and whether the company has upcoming catalysts (earnings, trial updates) not mentioned here.

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-08 for a 2026-06-05 insider sale

Background

This is an SEC Form 4 insider transaction disclosure for SI-BONE, Inc.

Company-level read

Ticker impact

$SIBNNeutralMedium confidence
Context

SI-BONE director Jeffrey W. Dunn sold 3,575 shares in an open-market transaction at $15.2462 on 2026-06-05.

Expected impact

Likely limited immediate impact; any effect would be sentiment-driven and small unless follow-on selling or new fundamentals emerge.

Evidence & confidence

The filing is a routine Form 4 insider sale with no 10b5-1 plan stated and no accompanying company-specific catalyst in the article.

Market effects

No clear sector read-through from a single director open-market sale.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification, taxes, or pre-planned liquidity needs; without a 10b5-1 plan, it still may not signal negative fundamentals.

Key entities

  • SI-BONE, Inc.

    Company whose director sold shares; subject of the Form 4 disclosure.

  • Jeffrey W. Dunn

    Director who executed the open-market sale of 3,575 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.